AZD0156: Selective ATM Kinase Inhibitor for Cancer Research

Principle and Setup: Harnessing ATM Kinase Inhibition in Cancer Biology

In the era of precision oncology, the DNA damage response (DDR) pathway has emerged as a critical therapeutic target. The ataxia telangiectasia mutated (ATM) kinase is a master regulator of DNA double-strand break (DSB) repair, checkpoint control, and genomic stability. By orchestrating cellular responses to DNA damage, ATM not only maintains genomic integrity but also influences cell fate decisions—a fact exploited by cancer cells to evade therapy and promote survival. AZD0156 (CAS: 1821428-35-6), available from APExBIO (SKU: B7822), is a potent, orally bioavailable, and highly selective small-molecule ATM kinase inhibitor for cancer research. With sub-nanomolar inhibitory potency and over 1,000-fold selectivity relative to other PIKK family kinases, AZD0156 enables researchers to dissect ATM’s role in DDR and checkpoint regulation with unparalleled specificity.

Notably, ATM inhibition has demonstrated synergy with both DNA double-strand break agents and metabolic modulators, as evidenced by studies in high grade serous ovarian cancer (HGSOC) cell lines where ATM inhibitors boost the efficacy of drugs such as fenofibrate by inducing cellular senescence (Chen et al., 2020). These findings position AZD0156 as a cornerstone tool for investigating synthetic lethality, metabolic vulnerabilities, and next-generation combination therapies in solid tumor research.

Step-by-Step Workflow: Optimizing Experimental Design with AZD0156

1. Compound Preparation and Storage

• Upon receipt from APExBIO, verify that AZD0156 is delivered as a solid with purity ≥98% (HPLC/NMR validated).
• For stock solutions, dissolve AZD0156 in DMSO at ≥23.1 mg/mL using gentle warming (<40°C). For ethanol, up to 5.49 mg/mL is achievable. AZD0156 is insoluble in water—use organic solvents only.
• Aliquot stock solutions to minimize freeze-thaw cycles and store at -20°C. Long-term storage of solutions is discouraged; prepare fresh aliquots for each experimental series to ensure potency and reproducibility.

2. Experimental Planning: Dosing and Controls

• Determine the optimal working concentration based on preclinical cancer model sensitivity and published IC₅₀ values (typically in the low nanomolar range for ATM signaling inhibition).
• Always include vehicle (DMSO or ethanol) controls at corresponding solvent concentrations.
• For combination studies (e.g., with PARP inhibitors, irradiation, or metabolic modulators like fenofibrate), use isobologram or Bliss synergy analyses to quantify combinatorial effects.

3. Cellular Assays: DDR and Checkpoint Modulation

• Apply AZD0156 to cancer cell lines (e.g., HGSOC, breast, or lung carcinoma) and monitor DDR markers: γH2AX (DSB marker), p-ATM, and downstream effectors (CHK2, p53 phosphorylation).
• Assess cell cycle checkpoint engagement via flow cytometry to track G1/S and G2/M arrest.
• For functional DNA double-strand break repair assays, perform immunofluorescence or comet assays post-treatment.

4. In Vivo and Translational Studies

• For preclinical cancer models, administer AZD0156 orally, following pharmacokinetic/pharmacodynamic optimization. In published studies, oral dosing regimens have potentiated antitumor responses to DSB-inducing agents with minimal off-target toxicity (see related workflow).
• Monitor endpoints such as tumor volume, survival, and DDR pathway activation in tumor tissues.

Advanced Applications and Comparative Advantages

1. Synthetic Lethality and Combination Therapy

ATM kinase inhibitors like AZD0156 unlock synthetic lethality strategies in cancers with intact homologous recombination (HR) pathways. While PARP inhibitors are effective in HR-deficient tumors, nearly 50% of HGSOC patients retain HR proficiency and remain resistant to these therapies (Chen et al., 2020). AZD0156 enables researchers to target this subset by sensitizing tumors to DNA-damaging agents or by combining with metabolic therapies such as PPARα agonists, leading to senescence and growth arrest in otherwise resistant cell populations.

These combinatorial effects can be quantified through synergy scoring, cell viability assays, and senescence markers (e.g., β-galactosidase staining). In the cited Heliyon study, ATM inhibition with AZD compounds plus fenofibrate achieved robust synergistic cytotoxicity in multiple HGSOC cell lines, highlighting the translational potential of this approach.

2. Metabolic Vulnerability Mapping

Recent research reveals that ATM activity intersects with cellular metabolism, making ATM inhibitors valuable not only as classic DDR pathway modulators but also as tools for metabolic reprogramming studies (complementary insights). AZD0156 can be deployed to probe metabolic dependencies in cancer cells, especially when used in tandem with agents modulating fatty acid oxidation or glycolysis. Such dual targeting may unveil new therapeutic windows, particularly in solid tumors with high metabolic plasticity.

3. Benchmarking Against Other ATM Kinase Inhibitors

Compared to earlier-generation ATM inhibitors, AZD0156 offers:

• Sub-nanomolar ATM inhibition, ensuring robust and rapid pathway suppression.
• Over 1,000-fold selectivity versus other PIKK family kinases (e.g., DNA-PK, mTOR), minimizing off-target effects that can confound experimental outcomes.
• Excellent oral bioavailability, facilitating in vivo translational studies.

These attributes establish AZD0156 as the gold standard for checkpoint control research and genomic stability studies (see comparative analysis).

Troubleshooting and Optimization Tips

• Solubility issues: If AZD0156 does not dissolve at the expected concentration in DMSO, gently warm the solution up to 40°C. Avoid excessive heat or sonication, which can degrade the compound.
• Precipitation on dilution: AZD0156 is insoluble in water and may precipitate when diluted into aqueous buffers. Dilute stocks into pre-warmed cell culture medium containing serum and deliver rapidly to cells. Keep final DMSO concentration ≤0.1% to minimize cell toxicity.
• Batch-to-batch consistency: Confirm purity via HPLC or NMR if unexpected results occur. APExBIO supplies AZD0156 with ≥98% purity, but in-house validation is recommended for critical experiments.
• Loss of activity over time: Prepare fresh working stocks for each assay. Prolonged storage, especially at room temperature or repeated freeze-thaw cycles, can compromise inhibitor potency.
• Off-target effects: Although AZD0156 is highly selective, monitor non-ATM PIKK signaling (e.g., p-mTOR, p-DNA-PK) as part of your control panel to ensure specificity in complex models.

For more scenario-driven troubleshooting, see this evidence-based guide which outlines practical solutions to common lab challenges with AZD0156.

Future Outlook

The research landscape for ATM kinase inhibitors is rapidly evolving. Ongoing early-phase clinical trials of AZD0156 in advanced cancers will yield crucial data on safety, efficacy, and biomarker-driven patient selection. In the laboratory, AZD0156 continues to enable innovative research into DNA damage response pathways, cell cycle checkpoint modulation, and metabolic adaptation—opening doors to new synthetic lethality and combination therapy paradigms. As more is learned about ATM’s role in cancer biology and therapy resistance, AZD0156 is poised to remain a foundational tool for both mechanistic and translational research.

In summary, AZD0156 empowers researchers to interrogate the DNA damage response, exploit metabolic vulnerabilities, and drive the next wave of cancer therapeutic research. For robust, reproducible outcomes, leverage the troubleshooting tips above and stay abreast of the latest comparative analyses and workflow enhancements from APExBIO and the broader DDR research community.